AFFIMED GMBH
12Patents
12Active
12Granted
44Portfolio score
Filing activity: May 26, 2006 → Oct 19, 2022 · 1 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9035026B2 | Anti-CD16 binding molecules | Chemistry; Metallurgy | 19 | Active |
| US9226962B2 | Human CD3-specific antibody with immunosuppressive properties | Chemistry; Metallurgy | 16 | Active |
| US10066015B2 | CD3 binding domains | Chemistry; Metallurgy | 5 | Active |
| US9701750B2 | Anti-CD16 binding molecules | Chemistry; Metallurgy | 4 | Active |
| US11510972B2 | Bispecific EGFR/CD16 antigen-binding protein | Chemistry; Metallurgy | 1 | Active |
| US12076384B2 | Bispecific EGFR/CD16 antigen-binding protein | Chemistry; Metallurgy | 0 | Active |
| US11001633B2 | NK cell engaging antibody fusion constructs | Chemistry; Metallurgy | 0 | Active |
| US11167029B2 | Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy | Chemistry; Metallurgy | 0 | Active |
| US11535672B2 | Combination of an anti-CD16A antibody with a cytokine | Chemistry; Metallurgy | 0 | Active |
| US11572415B2 | Multivalent FV antibodies | Chemistry; Metallurgy | 0 | Active |
| US12264198B2 | Tandem diabody for CD16A-directed NK-cell engagement | Chemistry; Metallurgy | 0 | Active |
| US11180558B2 | Tandem diabody for CD16A-directed NK-cell engagement | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.